# Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

> **NCT05918302** · PHASE3 · RECRUITING · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 170 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Lung Neuroendocrine Neoplasm
- Thymus Neoplasms

## Interventions

- **DRUG:** 177Lu-edotreotide
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT05918302
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-27
- **Primary completion:** 2029-03
- **Final completion:** 2029-10
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-05-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918302, "Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT05918302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*